San Diego-based biotech Inhibrx is claiming that it outperformed Merck’s Keytruda in a difficult-to-treat cancer. The combination of Keytruda and Inhibrx’s experimental drug INBRX-106 shrank more tumors than Keytruda alone in patients with metastatic head ...

Send this story to anyone — or drop the embed into a blog post, Substack, Notion page. Every play sends rev-share back to Endpoints News.

𝕏 Post on X in Share on LinkedIn ✉ Email a friend

Heard via Storyflo

Get audio versions of every article you read.

Pick what matters — your audio curator gets you into your daily flo.

Join the listener waitlist